Develops improved pharmaceuticals and digital therapies addressing unmet patient needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide.
Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo headquarters, where research and development is also performed, are situated in Uppsala, Sweden.